Compare IONQ Inc (IONQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? IONQ Inc trades at $39.56 (market cap $15.98B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8× IONQ Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IONQ | VRTX | |
|---|---|---|
Market Cap | $15.98B | $127.55B |
Volume | 22,848,240 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $82.09 | $557.96 |
52-Week Low | $26.59 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $13.92B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $41.34, down 4.5% today, with a mixed technical signal leaning bullish overall. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, reflecting high growth spending. Recent news highlights strong analyst backing, including Bank of America's Buy rating and $60 target, citing IonQ's trapped-ion quantum computing technology and partnerships.
Outlook: IonQ offers high growth potential in quantum computing, supported by bullish analyst targets averaging $62.75. Risks include persistent losses, cash burn, and intense competition. Investors should weigh the long-term disruptive potential against current profitability challenges and valuation premiums.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
